Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
about
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesNew trends in molecular and cellular biomarker discovery for colorectal cancerGenomic diversity of colorectal cancer: Changing landscape and emerging targetsSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraNovel therapeutic agents in the treatment of metastatic colorectal cancerNew therapeutic strategies for BRAF mutant colorectal cancersMolecular profiling in the treatment of colorectal cancer: focus on regorafenibBRAF Mutation in Colorectal Cancer: An UpdateSimilar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceCIViC databaseCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.RAS and BRAF in metastatic colorectal cancer managementMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerNegative feedback regulation of the ERK1/2 MAPK pathwayColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal CancerSynergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer.New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerVE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancerMolecular Biomarkers in the Personalized Treatment of Colorectal Cancer.BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.Colorectal clinical trials: what is on the horizon?Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.BRAF in metastatic colorectal cancer: the future starts now.Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.The kinome 'at large' in cancer.New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
P2860
Q26738801-2F393A87-5B62-441C-85F2-21A19658C3F5Q26739049-BE510A20-30A8-4865-80CC-7C2F19829773Q26739052-0A67EE17-533E-4D2C-8CA8-913106B723DBQ26751035-E588BA90-666B-4944-A576-053D5CB543C5Q26751344-B5280035-2C89-40EB-A34F-81938B870A9EQ26769932-B51309F1-1B7C-4139-999E-B44D0A4265AFQ26772277-B7B1C755-C858-4F45-AE9E-EA1409117C0AQ26778296-EEA6EEDC-2A51-4F5A-B45F-625D25A2249DQ26781926-26AB4275-396A-4EAC-9C7F-181779C53236Q26795609-327495C8-3A20-49D9-A303-1C7DECBACD15Q27612411-0DA3099C-5AB6-4D5A-9477-6748E539A9BEQ27853216-A0D89050-37A1-4E91-8EF7-5D07752ECD80Q27853224-4FB3F329-D841-4BAE-A4C4-53956B11318DQ28074175-AF012E06-5882-4B1E-9BB9-4BE6F22B4A15Q28076490-1C55A8F5-E2CC-4D14-AB12-663743C03A72Q28079202-03110D78-DBA3-4A02-8088-34EE1C13104BQ30238915-3AD41C9E-3D46-43A8-BD3A-4DDB0187B609Q33618353-D3BDB5CC-F5D0-4A8E-BF17-89968F4B1CD0Q33731804-4638985A-A3AB-487B-BF64-077D6458FFDFQ33767369-9848AE30-F820-41EB-8590-3C41500A1941Q35586700-31A1260A-947C-4EB5-977B-57DCCD999446Q36352341-900F1A24-36E2-4E6A-ADD5-33F6F79BB267Q36359700-69ABC56D-046A-49F9-8295-B39E958267F5Q36432094-529CB114-4231-4EC2-BE24-7008C103165EQ36561520-3622BAC1-8165-4EDE-9308-97DC5ABEBE4DQ36813582-B10A3165-DC53-4085-9EC2-156E87C6FA9EQ36962548-5DE71EBB-2E7A-4551-9094-30B7E7DE5492Q37157958-990DC0FF-F1E4-40B1-8FD3-F8C84ECC5965Q37536016-23848182-523D-42B5-B10C-75D08A14107EQ38481038-66361C30-AC2A-42B0-8250-B076378B5FB6Q38569221-783D477E-83D1-4810-98C5-451CA1CB2115Q38625131-F3B6FC82-C3E6-44FB-B7BD-68B3DE6C60FEQ38648300-03ADF3A5-0DDF-4B70-8970-F915D7F19D12Q38650454-36E1C8EF-F68B-4915-B9F6-127688B4E728Q38652005-677A747B-ABC9-4B4A-9D9F-60165FE252F2Q38652294-4D0E3FB5-D43A-4D29-8E21-7156F58F784BQ38679229-0E679ACE-2902-4ED0-AF18-58A403593F3BQ38715428-739CB642-538F-49FC-8302-401ABA757634Q38727912-35DC4FEC-8E33-4359-A76D-0176214A328FQ38730744-2306A6F2-C438-4029-A5C5-739467CCCCDC
P2860
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@ast
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@en
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@nl
type
label
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@ast
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@en
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@nl
prefLabel
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@ast
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@en
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@nl
P2093
P2860
P50
P3181
P1476
Pilot trial of combined BRAF a ...... ic colorectal cancer patients.
@en
P2093
Andrea Cercek
Diane L Reidy
Efsevia Vakiani
Marc J Gollub
Marinela Capanu
Michael F Berger
Nancy Kemeny
Neal Rosen
Rona Yaeger
Tamar Wolinsky
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-14-2779
P407
P577
2015-01-14T00:00:00Z